Clinical Report: Updates on Local Steroids for Uveitis Management
Overview
Recent changes in the availability and approval of local steroid therapies for uveitis have significant clinical implications. Notably, the discontinuation of Retisert and the relaunch of Triesence with a substantial price increase mark a new phase in uveitis care.
Background
Local steroids are a cornerstone in managing uveitic conditions, providing intraocular inflammation control without systemic immunosuppression. The fluocinolone acetonide intravitreal implant Retisert, approved in 2005, has been effective but associated with cataracts and glaucoma risks. Other options include injectable implants like Yutiq and dexamethasone-based Ozurdex. Market dynamics, including FDA approvals, manufacturing challenges, and corporate acquisitions, have recently altered the landscape of these therapies.
Data Highlights
| Product | Active Ingredient | Dose | Duration | FDA Approval Indication | Notable Risks/Features | Recent Changes |
|---|---|---|---|---|---|---|
| Retisert | Fluocinolone acetonide | 0.59 mg | ~30 months | Chronic noninfectious posterior uveitis | Cataracts in nearly all phakic eyes by 3 years; 77% needed IOP-lowering meds; 37% required glaucoma surgery | Discontinuation announced for April 2026 due to manufacturing issues |
| Triesence | Triamcinolone acetonide | 40 mg/mL injectable suspension | Short-acting injectable | Sympathetic ophthalmia, temporal arteritis, noninfectious uveitis, other ocular inflammation, vitrectomy aid | Preservative-free formulation; faced prolonged shortage; 486% price increase on relaunch | Relaunched late 2024 by Harrow with stabilized supply |
| Yutiq | Fluocinolone acetonide | 0.18 mg | Up to 36 months | Chronic noninfectious posterior uveitis | Injectable intravitreal insert | US commercial rights transferred to Alimera, then acquired by ANI Pharmaceuticals in 2024 |
| Iluvien | Fluocinolone acetonide | 0.19 mg | Long-acting implant | Originally diabetic macular edema; expanded to chronic noninfectious posterior uveitis in US | Approved in Europe and Middle East for uveitis | Label expanded in 2024 post ANI acquisition |
| Ozurdex | Dexamethasone | 0.7 mg | Short-acting implant | Various intraocular inflammatory conditions | Alternative to Retisert and Yutiq | Available as alternative treatment |
Key Findings
- Retisert, a 0.59 mg fluocinolone acetonide implant with ~30 months duration, will be discontinued in April 2026 due to manufacturing component shortages.
- Retisert significantly reduces uveitis recurrences and systemic immunosuppression reliance but carries high risks of cataracts and glaucoma interventions.
- Triesence, a preservative-free triamcinolone injectable, was unavailable during 2020–2022 but relaunched in late 2024 with a 486% price increase.
- Yutiq, a 0.18 mg fluocinolone acetonide injectable implant approved in 2018, provides up to 36 months of steroid release for chronic noninfectious posterior uveitis; commercial rights changed hands multiple times, now owned by ANI Pharmaceuticals.
- Iluvien, originally approved for diabetic macular edema, had its US label expanded in 2024 to include chronic noninfectious posterior uveitis, aligning with European indications.
- No currently approved implant matches Retisert’s dose and duration, necessitating consideration of alternative therapies or systemic immunosuppression adjustments.
Clinical Implications
Clinicians should prepare for Retisert’s discontinuation by evaluating alternative local steroid options such as Yutiq and Ozurdex or adjusting systemic therapies. The relaunch of Triesence offers a preservative-free injectable option but at a significantly higher cost, which may impact treatment decisions. Awareness of label expansions, especially for Iluvien, broadens therapeutic choices for chronic noninfectious posterior uveitis.
Conclusion
The evolving availability and regulatory landscape of local steroid therapies for uveitis require clinicians to adapt treatment strategies. Despite challenges, multiple intravitreal steroid options remain to effectively manage intraocular inflammation while minimizing systemic exposure.
References
- RP -- An Update on Local Steroids for Uveitis
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
